

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Company 2022/07/01 22:00:00

Price
595.40
 USD

Difference ▲ 0.72%(4.27)

REGENERON



Contact Details

REGENERON PHARMACEUTICALS INC.
 - -
 777 Old Saw Mill River Road
 10591-6707 Tarrytown

Tel: 1-914-847-7000
 Fax: -
 Web: <http://www.regeneron.com>
 E-mail: -

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as Velocimmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2021 | | 2020 | | 2019 | |
|--------------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 14,014,900,000 | | 9,779,100,000 | | 7,689,100,000 | |
| Common stock capital | | 100,000 | | 100,000 | | 100,000 |
| Fixed assets | 11,419,900,000 | | 7,384,200,000 | | 7,116,100,000 | |
| Equity capital of a company | | 18,768,800,000 | | 11,025,300,000 | | 11,089,700,000 |
| Cash and cash equivalents | 2,885,600,000 | | 2,193,700,000 | | 1,617,800,000 | |
| Accrued liabilities | | 0 | | 0 | | 0 |
| Other assets | - | | - | | - | |
| Current liabilities | | 3,932,500,000 | | 2,697,400,000 | | 2,096,600,000 |
| Prepayments and accrued income | | - | | - | | - |
| Non-current liabilities | | 2,733,500,000 | | 3,440,600,000 | | 1,618,900,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 753,500,000 | | 744,900,000 | | 905,000,000 |
| Total assets | 25,434,800,000 | 25,434,800,000 | 17,163,300,000 | 17,163,300,000 | 14,805,200,000 | 14,805,200,000 |

Balance notes

| | 2021 | 2020 | 2019 |
|---------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 10,368 | 9,123 | 8,100 |
| Equity ratio | 73.79% | 64.24% | 74.90% |
| Debt-equity ratio | 35.52% | 55.67% | 33.50% |

Others

| | 2021 | 2020 | 2019 |
|------------------|--------|-------|--------|
| Tax Expense Rate | 13.41% | 7.80% | 12.90% |

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Income statement

| | 2021 | 2020 | 2019 |
|--|----------------|---------------|---------------|
| Turnover | 16,071,700,000 | 8,497,100,000 | 7,863,400,000 |
| Net income | 8,075,300,000 | 3,513,200,000 | 2,115,800,000 |
| EBIT | 8,998,392,900 | 3,708,740,700 | 2,358,468,700 |
| Operating income before taxes | 9,325,800,000 | 3,810,400,000 | 2,429,100,000 |
| Cash Flow | 7,081,300,000 | 2,618,100,000 | 2,430,000,000 |
| Net interest income | -57,300,000 | -56,900,000 | -30,200,000 |
| Research and development expenses | 2,621,900,000 | 2,499,100,000 | 2,826,300,000 |
| Income taxes | 1,250,500,000 | 297,200,000 | 313,300,000 |
| Result from investments in subsidiaries, associates and other | - | - | - |
| Revenues per employee | 1,486,570 | 893,206 | 930,988 |

Board of Directors

Members of Management Board

| | |
|-----------------------|--------------------------------|
| P. Vagelos | Chairman of Board of Directors |
| Bonnie Bassler | Member of Board of Directors |
| George Yancopoulos | Member of Board of Directors |
| Huda Zoghbi | Member of Board of Directors |
| Joseph Goldstein | Member of Board of Directors |
| Marc Tessier-Lavigne | Member of Board of Directors |
| Michael Brown | Member of Board of Directors |
| N. Coles | Member of Board of Directors |
| Arthur Ryan | Member of Board of Directors |
| Christine Poon | Member of Board of Directors |
| George Sing | Member of Board of Directors |
| Leonard S. Schleifer | Chairman of Managing Board |
| George D. Yancopoulos | Member of Executive Committee |
| Robert E. Landry | Member of Executive Committee |